MedDataX Logo

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

NCT ID: NCT00370370

Last Updated: 2008-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Age-Related Macular Degeneration

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bevacizumab, Triamcinolone Age-related macular degeneration Choroidal neovascular membrane

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Injection of intravitreal bevacizumab

Group Type ACTIVE_COMPARATOR

bevacizumab

Intervention Type DRUG

Injection of intravitreal bevacizumab

2

Injection of bevacizumab + triamcinolone acetonide

Group Type ACTIVE_COMPARATOR

bevacizumab + triamcinolone acetonide

Intervention Type DRUG

Injection of bevacizumab + triamcinolone acetonide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

Injection of intravitreal bevacizumab

Intervention Type DRUG

bevacizumab + triamcinolone acetonide

Injection of bevacizumab + triamcinolone acetonide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria

* History of glaucoma or ocular hypertension
* Disciform scar
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shahid Beheshti University of Medical Sciences

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hamid Ahmadieh, MD

Role: PRINCIPAL_INVESTIGATOR

Ophthalmic Research Center of Shaheed Beheshti Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hamid Ahmadieh, MD

Tehran, Tehran Province, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8533

Identifier Type: -

Identifier Source: org_study_id